Immune checkpoint pathways have garnered a lot of attention over the years as promising targets for cancer immunotherapy. Inhibitory checkpoint molecules such as PD-1 and CTLA-4 have proven to be reliable targets, but some patients still don’t respond to these treatments or quickly relapse. As a result, the search for effective targets continues. A recent literature search revealed ten new, noteworthy targets with promising therapeutic potential. Download the related infographic for an inside scoop on those targets, including BLIMP1 and STING.
Please check the highlighted fields and try again.